Unternehmen in BERLIN

CHECKIMMUNE GMBH

BeobachtenFeed abonnierenFörderungen als CSV

In 0 Bekanntmachungen genannt, seit 1. Januar 2022, aber in keiner als Auftragnehmer eines Zuschlags.

Fördermittel

Kohesio und Finanztransparenzsystem der EU, so gezählt.

5 Förderungen, zusammen 681.581 €.

QuelleBetragFörderungen
EU-Haushalt (Finanztransparenzsystem)681.581 €55
JahrProgrammProjektBetrag und Beleg
2024EU Budget - European CommissionHADEA - European Health and Digital Executive Agency101057438 - GENETIGA - GENE-EDITED T CELLS COMBATING IGA NEPHROPATHY. A BLUEPRINT APPROACH FOR SAFE & EFFICIENT GENOME EDITING OF T CELLS TO SUSTAINABLY COMBAT SEVERAL IMMUNE DISEASES AND CANCERS RELATED TO B-CELL PATHOLOGY101057438 - GENETIGA - GENE-EDITED T CELLS COMBATING IGA NEPHROPATHY. A BLUEPRINT APPROACH FOR SAFE & EFFICIENT GENOME EDITING OF T CELLS TO SUSTAINABLY COMBAT SEVERAL IMMUNE DISEASES AND CANCERS RELATED TO B-CELL PATHOLOGY51.249 €Mittelbindung
2024EU Budget - European CommissionHADEA - European Health and Digital Executive Agency101156595 - ERDERA - EUROPEAN RARE DISEASES RESEARCH ALLIANCE101156595 - ERDERA - EUROPEAN RARE DISEASES RESEARCH ALLIANCE131.501 €Mittelbindung
2022EU Budget - European CommissionHADEA - European Health and Digital Executive Agency101057438 - GENETIGA - GENE-EDITED T CELLS COMBATING IGA NEPHROPATHY. A BLUEPRINT APPROACH FOR SAFE & EFFICIENT GENOME EDITING OF T CELLS TO SUSTAINABLY COMBAT SEVERAL IMMUNE DISEASES AND CANCERS RELATED TO B-CELL PATHOLOGY101057438 - GENETIGA - GENE-EDITED T CELLS COMBATING IGA NEPHROPATHY. A BLUEPRINT APPROACH FOR SAFE & EFFICIENT GENOME EDITING OF T CELLS TO SUSTAINABLY COMBAT SEVERAL IMMUNE DISEASES AND CANCERS RELATED TO B-CELL PATHOLOGY232.805 €Mittelbindung
2022EU Budget - European CommissionHADEA - European Health and Digital Executive Agency101057438 - GENETIGA - GENE-EDITED T CELLS COMBATING IGA NEPHROPATHY. A BLUEPRINT APPROACH FOR SAFE & EFFICIENT GENOME EDITING OF T CELLS TO SUSTAINABLY COMBAT SEVERAL IMMUNE DISEASES AND CANCERS RELATED TO B-CELL PATHOLOGY101057438 - GENETIGA - GENE-EDITED T CELLS COMBATING IGA NEPHROPATHY. A BLUEPRINT APPROACH FOR SAFE & EFFICIENT GENOME EDITING OF T CELLS TO SUSTAINABLY COMBAT SEVERAL IMMUNE DISEASES AND CANCERS RELATED TO B-CELL PATHOLOGY241.085 €Mittelbindung
2022EU Budget - European CommissionHADEA - European Health and Digital Executive Agency101057438 - GENETIGA - GENE-EDITED T CELLS COMBATING IGA NEPHROPATHY. A BLUEPRINT APPROACH FOR SAFE & EFFICIENT GENOME EDITING OF T CELLS TO SUSTAINABLY COMBAT SEVERAL IMMUNE DISEASES AND CANCERS RELATED TO B-CELL PATHOLOGY101057438 - GENETIGA - GENE-EDITED T CELLS COMBATING IGA NEPHROPATHY. A BLUEPRINT APPROACH FOR SAFE & EFFICIENT GENOME EDITING OF T CELLS TO SUSTAINABLY COMBAT SEVERAL IMMUNE DISEASES AND CANCERS RELATED TO B-CELL PATHOLOGY24.942 €Mittelbindung

Angaben aus den Bekanntmachungen

0 Nennungen seit 1. Januar 2022, zuletzt am 1. Januar 2022, dieser Organisation zugeordnet. Wie wir zuordnen

Anschrift
CAMPUS VIRCHOW KLINIKUM, CRANACH HA, 13353 BERLIN
USt-IdNr.
DE322169472
Schreibweisen
  • CHECKIMMUNE GMBH